Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q3 2013 · 10-Q
Revenue$95.00K$95.00K— vs Q3 2012 Net Income-$2.65M-$2.65MN/M vs Q3 2012 EPS Diluted-$1.88-$1.88N/M vs Q3 2012 Operating Income-$2,647,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-2786.3%
Net margin-2785.3%
ended Sep 30, 2013 · filed Nov 13, 2013 · 44 d after period end